公开(公告)号：US20240269121A1

公开(公告)日：2024-08-15

申请号：US18567464

申请日：2022-06-08

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Ofer TOLEDANO ,  Karine NEIMANN ,  Hila HAKAK DJERBI

IPC: A61K31/44 ,  A61K31/05 ,  A61K31/194 ,  A61K31/196 ,  A61K31/202 ,  A61K31/277 ,  A61K31/327 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/4164 ,  A61K31/42 ,  A61K31/421 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/473 ,  A61K31/519 ,  A61K31/65 ,  A61K31/69 ,  A61K31/7048 ,  A61K45/06

CPC classification number: A61K31/44 ,  A61K31/05 ,  A61K31/194 ,  A61K31/196 ,  A61K31/202 ,  A61K31/277 ,  A61K31/327 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/4164 ,  A61K31/42 ,  A61K31/421 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/473 ,  A61K31/519 ,  A61K31/65 ,  A61K31/69 ,  A61K31/7048 ,  A61K45/06

Abstract: The present invention relates to a method of reducing acne relapse or rosacea relapse rate or severity, by reducing the skin's immunological response, wherein the method comprises administering a topical composition comprising at least one of a PDE4 inhibitor, a JAK inhibitor, an AhR modulator, or any combination thereof.

公开(公告)号：US20230404917A1

公开(公告)日：2023-12-21

申请号：US18037568

申请日：2021-11-17

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Ofer TOLEDANO ,  Karine NEIMANN

IPC: A61K9/06 ,  A61K9/00 ,  A61K31/519 ,  A61K45/06

CPC classification number: A61K9/06 ,  A61K9/0014 ,  A61K31/519 ,  A61K45/06

Abstract: This invention, in some embodiments thereof, relates to regimens, topical compositions comprising ruxolitinib, deuterated ruxolitinib or pharmaceutically acceptable salt thereof and uses thereof for the treatment of inflammatory skin conditions.

公开(公告)号：US20230310395A1

公开(公告)日：2023-10-05

申请号：US18022522

申请日：2021-08-24

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Ofer TOLEDANO ,  Karine NEIMANN ,  Hila HAKAK DJERBI

IPC: A61K31/44 ,  A61K9/00 ,  A61K9/06 ,  A61K47/26 ,  A61K47/10 ,  A61K47/18 ,  A61K47/32 ,  A61K47/12 ,  A61K47/14 ,  A61K47/06 ,  A61P17/00

CPC classification number: A61K31/44 ,  A61K9/0014 ,  A61K9/06 ,  A61K47/26 ,  A61K47/10 ,  A61K47/183 ,  A61K47/32 ,  A61K47/12 ,  A61K47/14 ,  A61K47/06 ,  A61P17/00

Abstract: The present disclosure, in some embodiments, relates to a low permeable topical composition comprising roflumilast, N-oxide of roflumilast or salts thereof, and to a method of treatment of a skin disorder by topical administration of said composition.

公开(公告)号：US20230248687A1

公开(公告)日：2023-08-10

申请号：US18123702

申请日：2023-03-20

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer TOLEDANO ,  Ori NOV

IPC: A61K31/327 ,  A61K9/00 ,  A61K9/50 ,  A61K9/06 ,  A61P17/00

CPC classification number: A61K31/327 ,  A61K9/06 ,  A61K9/0014 ,  A61K9/50 ,  A61P17/00

Abstract: A regimen and a pharmaceutical composition for the treatment of a skin condition and/or skin affliction are described. The regimen includes topically applying to the skin of a subject in need of such treatment a pharmaceutical composition comprising about 2.5% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient.

公开(公告)号：US11633399B2

公开(公告)日：2023-04-25

申请号：US16737503

申请日：2020-01-08

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Moshe Arkin ,  Marcel Zighelboim ,  Ori Nov ,  Ofer Toledano ,  Karine Neimann

IPC: A61K31/505 ,  A61K31/517 ,  A61K31/5377 ,  A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K31/05 ,  A61K9/06 ,  A61K31/506

Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

公开(公告)号：US20230000786A1

公开(公告)日：2023-01-05

申请号：US17779151

申请日：2020-11-24

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Karine NEIMANN

IPC: A61K31/047 ,  A61K31/44 ,  A61K31/4035 ,  A61K31/69 ,  A61K31/203 ,  A61K45/06 ,  A61K9/00

Abstract: Provided herein is a topical combination composition comprising tapinarof, a PDE4 inhibitor and optionally at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder selected from psoriasis, dermatitis, acne, rosacea, ichthyosis, scaling skin, imbalance of skin barrier and tinea and exhibit synergistic and/or additive effects allowing to reduce the active agents amounts in the combination compositions.

公开(公告)号：US20220331268A1

公开(公告)日：2022-10-20

申请号：US17763236

申请日：2020-09-24

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM

IPC: A61K31/05 ,  A61K9/00 ,  A61K31/496 ,  A61K31/235 ,  A61K31/203 ,  A61K31/192 ,  A61K31/4436 ,  A61K31/519 ,  A61K31/222 ,  A61K31/7048 ,  A61K31/167 ,  A61K9/48

Abstract: Provided herein is a topical combination composition comprising tapinarof, an additional AhR activator and optionally further comprising at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder and exhibit synergistic and/or additive effects which allow reducing the amounts of the active agents in the compositions.

公开(公告)号：US20220287990A1

公开(公告)日：2022-09-15

申请号：US17629424

申请日：2020-07-23

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Marcel ZIGHELBOIM ,  Ori NOV ,  Ofer TOLEDANO

IPC: A61K31/05 ,  A61K9/00 ,  A61K31/327 ,  A61K31/519 ,  A61K31/203 ,  A61K31/192 ,  A61K31/4436 ,  A61K31/4709 ,  A61K31/65 ,  A61K31/7056 ,  A61K31/7048 ,  A61K9/06

Abstract: Provided herein is a topical combination composition and a method of treatment of an inflammatory skin condition by administration of said composition comprising at least one Janus kinase inhibitor (JAK inhibitor) and at least one additional active agent elected from benzoyl peroxide (BPO), at least one retinoid, tapinarof, at least one antibiotic, at least one antiandrogen, at least one acaricide and combinations thereof and a carrier suitable for topical administration. The JAK inhibitor and the at least one additional active agent exhibit an additive or synergistic effect, allowing to reduce the amounts of active agents in the composition.

公开(公告)号：US11426378B2

公开(公告)日：2022-08-30

申请号：US16794887

申请日：2020-02-19

Applicant: Sol-Gel Technologies Ltd.

Inventor： Ofer Toledano ,  Ofra Levy-Hacham ,  Ori Nov ,  Vered Ram

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/107 ,  A61K9/00 ,  A61K9/06 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75%.

公开(公告)号：US20220175802A1

公开(公告)日：2022-06-09

申请号：US17440780

申请日：2020-03-19

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe ARKIN ,  Karine NEIMANN ,  Danil FINKEL-MOISEEV

IPC: A61K31/65 ,  A61K31/327 ,  A61K9/00 ,  A61K9/06 ,  A61K47/34 ,  A61K47/44 ,  A61K47/10 ,  A61K47/02 ,  A61K47/12

Abstract: This invention is directed to a regimen administration of combination of minocycline and benzoyl peroxide and uses thereof for treating a skin disorder such as acne or rosacea.